GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (NAS:TNDM) » Definitions » Net Margin %
中文

Tandem Diabetes Care (Tandem Diabetes Care) Net Margin % : -15.25% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Tandem Diabetes Care Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Tandem Diabetes Care's Net Income for the three months ended in Dec. 2023 was $-30.0 Mil. Tandem Diabetes Care's Revenue for the three months ended in Dec. 2023 was $196.8 Mil. Therefore, Tandem Diabetes Care's net margin for the quarter that ended in Dec. 2023 was -15.25%.

The historical rank and industry rank for Tandem Diabetes Care's Net Margin % or its related term are showing as below:

TNDM' s Net Margin % Range Over the Past 10 Years
Min: -159.94   Med: -48.23   Max: 2.21
Current: -29.77


TNDM's Net Margin % is ranked worse than
65.07% of 816 companies
in the Medical Devices & Instruments industry
Industry Median: 0.045 vs TNDM: -29.77

Tandem Diabetes Care Net Margin % Historical Data

The historical data trend for Tandem Diabetes Care's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tandem Diabetes Care Net Margin % Chart

Tandem Diabetes Care Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.83 -6.89 2.21 -11.81 -29.77

Tandem Diabetes Care Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.19 -73.13 -18.26 -17.76 -15.25

Competitive Comparison of Tandem Diabetes Care's Net Margin %

For the Medical Devices subindustry, Tandem Diabetes Care's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tandem Diabetes Care's Net Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Net Margin % distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Net Margin % falls into.



Tandem Diabetes Care Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Tandem Diabetes Care's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-222.611/747.718
=-29.77 %

Tandem Diabetes Care's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-30.002/196.796
=-15.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tandem Diabetes Care  (NAS:TNDM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Tandem Diabetes Care Net Margin % Related Terms

Thank you for viewing the detailed overview of Tandem Diabetes Care's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tandem Diabetes Care (Tandem Diabetes Care) Business Description

Traded in Other Exchanges
Address
11075 Roselle Street, San Diego, CA, USA, 92121
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Executives
Dick Allen director 11045 ROSELLE STREET, SAN DIEGO CA 92121
Shannon Marie Hansen officer: SVP & General Counsel C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Leigh Vosseller officer: Senior Vice President and CFO C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kathleen Mcgroddy-goetz director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Peyton R Howell director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
David B Berger officer: GENERAL COUNSEL 11045 ROSELLE STREET, SAN DIEGO CA 92121
Malagueira Joao Paulo Falcao director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Myoungil Cha director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kim D Blickenstaff director, officer: PRESIDENT AND CEO C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
John F Sheridan officer: EXECUTIVE VP AND COO C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
Christopher J Twomey director 4767 NEXUS CENTRE DRIVE, SAN DIEGO CA 92121
Rebecca B Robertson director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
James Leal officer: SVP, Operations C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Elizabeth Anne Gasser officer: EVP, Chief Strategy Officer C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Susan Morrison officer: CAO 11045 ROSELLE STREET, SAN DIEGO CA 92121

Tandem Diabetes Care (Tandem Diabetes Care) Headlines

From GuruFocus